Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Gupta, Aditi ^a   Cao, Wei ^b   Sadashivaiah, Kavitha ^a   Chen, Wantao ^b   Schneider, Abraham ^a   Chellaiah, Meenakshi A ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; CD44V6 ANTIGEN; GELATINASE B; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CANCER CELL; CELL ADHESION; CONTROLLED STUDY; GLYCOSYLATION; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TISSUE MICROARRAY; CELL MOTION; ENZYMOLOGY; FOCAL ADHESION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; STRESS FIBER; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIGENS, CD44; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; FOCAL ADHESIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; PHENOTYPE; PROSTATIC NEOPLASMS; STRESS FIBERS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874542110     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/493689     Document Type: Article

References (59)

1. Desai B., Rogers M. J., Chellaiah M. A., Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Molecular Cancer 2007 6, article 18 2-s2.0-33947413459 10.1186/1476-4598-6-18 (Pubitemid 46443394)
2. Draffin J. E., McFarlane S., Hill A., Johnston P. G., Waugh D. J. J., CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Research 2004 64 16 5702 5711 2-s2.0-4143149778 10.1158/0008-5472.CAN-04-0389 (Pubitemid 39095568)
3. Isacke C. M., Yarwood H., The hyaluronan receptor, CD44. International Journal of Biochemistry and Cell Biology 2002 34 7 718 721 2-s2.0-0036223281 10.1016/S1357-2725(01)00166-2 (Pubitemid 34304161)
4. Ponta H., Sleeman J., Dall P., Moll J., Sherman L., Herrlich P., CD44 isoforms in metastatic cancer. Invasion and Metastasis 1994 14 1-6 82 86 2-s2.0-0028675248
5. Naor D., Sionov R. V., Zahalka M., Rochman M., Holzmann B., Ish-Shalom D., Organ-specific requirements for cell adhesion molecules during lymphoma cell dissemination. Current Topics in Microbiology and Immunology 1998 231 143 166 2-s2.0-0031458711
6. Desai B., Ma T., Chellaiah M. A., Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion. The Journal of Biological Chemistry 2008 283 20 13856 13866 2-s2.0-46649093214 10.1074/jbc.M709401200
7. Robertson B. W., Chellaiah M. A., Osteopontin induces β -catenin signaling through activation of Akt in prostate cancer cells. Experimental Cell Research 2010 316 1 1 11 2-s2.0-70449701416 10.1016/j.yexcr.2009.10.012
8. Cichy J., Puré E., The liberation of CD44. The Journal of Cell Biology 2003 161 5 839 843 2-s2.0-0037780985 10.1083/jcb.200302098 (Pubitemid 36718417)
9. Rall C. J. N., Rustgi A. K., CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Research 1995 55 9 1831 1835 2-s2.0-0028948666
10. Yamane N., Tsujitani S., Makino M., Maeta M., Kaibara N., Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer. Oncology 1999 56 3 232 238 2-s2.0-0032906045 (Pubitemid 29161293)
11. Stevens J. W., Palechek P. L., Griebling T. L., Midura R. J., Rokhlin O. W., Cohen M. B., Expression of CD44 isoforms in human tumor cell lines. Prostate 1996 28 153 161 (Pubitemid 26110735)
12. Desai B., Ma T., Zhu J., Chellaiah M. A., Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. Journal of Cellular Biochemistry 2009 108 1 272 284 2-s2.0-76249122104
13. Lokeshwar B. L., Lokeshwar V. B., Block N. L., Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Research 1995 15 4 1191 1198 2-s2.0-0029092177
14. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., Reilly J. G., Chandra D., Zhou J., Claypool K., Coghlan L., Tang D. G., Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006 25 12 1696 1708 2-s2.0-33645026803 10.1038/sj.onc.1209327
15. Gao A. C., Lou W., Sleeman J. P., Isaacs J. T., Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Research 1998 58 11 2350 2352 2-s2.0-0032101137 (Pubitemid 28252693)
16. Pergolizzi R. G., Kreis W., Rottach C., Susin M., Broome J. D., Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. Cancer Investigation 1993 11 1 25 32 2-s2.0-0027476131 (Pubitemid 23041446)
17. Sanchez-Sweatman O. H., Orr F. W., Singh G., Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion and Metastasis 1998 18 5-6 297 305 2-s2.0-0032467396 (Pubitemid 30223705)
18. Schuurmans A. L. G., Bolt J., Mulder E., Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 1988 12 1 55 63 2-s2.0-0023944580
19. Choo C. K., Ling M. T., Chan K. W., Immortalization of human epithelial cells by HPV 16 E6/E7 open reading frames. Prostate 1999 40 150 158
20. Feng P., Li T. L., Guan Z. X., Franklin R. B., Costello L. C., Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 2002 52 4 311 318 2-s2.0-0036720332 10.1002/pros.10128
21. Hayward S. W., Dahiya R., Cunha G. R., Bartek J., Deshpande N., Narayan P., Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cellular & Developmental Biology 1995 31 1 14 24 2-s2.0-0029202881 10.1007/BF02631333
22. Hayward S. W., Wang Y., Cao M., Yun Kit Hom, Zhang B., Grossfeld G. D., Sudilovsky D., Cunha G. R., Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Research 2001 61 22 8135 8142 2-s2.0-0035890799 (Pubitemid 33091604)
23. Franklin R. B., Feng P., Milon B., Desouki M. M., Singh K. K., Kajdacsy-Balla A., Bagasra O., Costello L. C., hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Molecular Cancer 2005 4, article 32 2-s2.0-26844565027 10.1186/1476-4598-4-32 (Pubitemid 41461192)
24. Gupta A., Cao W., Chellaiah M. A., Integrin avb3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogensis via RUNX2/Smad5/RANKL. Signaling Axis 2012 11 1 18
25. Ma T., Sadashivaiah K., Chellaiah M. A., Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts. The Journal of Biological Chemistry 2010 285 39 29911 29924 2-s2.0-77956920121 10.1074/jbc.M109.099697
26. Samanna V., Wei H., Ego-Osuala D., Chellaiah M. A., Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Experimental Cell Research 2006 312 12 2214 2230 2-s2.0-33745253734 10.1016/j.yexcr.2006.03.022 (Pubitemid 43928940)
27. Chellaiah M., Kizer N., Silva M., Alvarez U., Kwiatkowski D., Hruska K. A., Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. The Journal of Cell Biology 2000 148 4 665 678 2-s2.0-0034695921 10.1083/jcb.148.4.665
28. Paszkiewicz-Gadek A., Gindzieński A., Porowska H., An improved method for chemical deglycosylation of gastric mucus glycoprotein. Roczniki Akademii Medycznej w Białymstoku 1997 42 1 18 25 2-s2.0-0031318870
29. Schneider A., Younis R. H., Gutkind J. S., Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 2008 10 11 1295 1302 2-s2.0-55849109650 10.1593/neo.08586
30. Heider K. H., Kuthan H., Stehle G., Munzert G., CD44v6: a target for antibody-based cancer therapy. Cancer Immunology, Immunotherapy 2004 53 7 567 579 2-s2.0-2342537511 10.1007/s00262-003-0494-4 (Pubitemid 38858330)
31. Chellaiah M. A., Kizer N., Biswas R., Alvarez U., Strauss-Schoenberger J., Rifas L., Rittling S. R., Denhardt D. T., Hruska K. A., Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Molecular Biology of the Cell 2003 14 1 173 189 2-s2.0-12244312775 10.1091/mbc.E02-06-0354 (Pubitemid 36106028)
32. Robertson B. W., Bonsal L., Chellaiah M. A., Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Molecular Cancer 2010 9, article 260 2-s2.0-77956893142 10.1186/1476-4598-9-260
33. Bowden E. T., Barth M., Thomas D., Glazer R., Mueller S. C., An invasion-related complex of cortactin, paxillin and PKC associates with invadopodia at sites of extracellular matrix degradation. Oncogene 1999 18 31 4440 4449 2-s2.0-0033527066 10.1038/sj.onc.1202827 (Pubitemid 29396652)
34. Buccione R., Orth J. D., McNiven M. A., Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nature Reviews Molecular Cell Biology 2004 5 8 647 657 2-s2.0-3543114271 10.1038/nrm1436 (Pubitemid 39025065)
35. Yamaguchi H., Pixley F., Condeelis J., Invadopodia and podosomes in tumor invasion. European Journal of Cell Biology 2006 85 3-4 213 218 2-s2.0-33644935220 10.1016/j.ejcb.2005.10.004
36. Kelly T., Mueller S. C., Yeh Y., Chen W. T., Invadopodia promote proteolysis of a wide variety of extracellular matrix proteins. Journal of Cellular Physiology 1994 158 2 299 308 2-s2.0-0028115933 (Pubitemid 24063557)
37. Weber G. F., Bronson R. T., Ilagan J., Cantor H., Schmits R., Mak T. W., Absence of the CD44 gene prevents sarcoma metastasis. Cancer Research 2002 62 8 2281 2286 2-s2.0-0037089521 (Pubitemid 34411705)
38. Orian-Rousseau V., CD44, a therapeutic target for metastasising tumours. European Journal of Cancer 2010 46 7 1271 1277 2-s2.0-77950561915 10.1016/j.ejca.2010.02.024
39. Clark E. S., Whigham A. S., Yarbrough W. G., Weaver A. M., Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Research 2007 67 9 4227 4235 2-s2.0-34249320529 10.1158/0008-5472.CAN-06-3928 (Pubitemid 46815069)
40. Lorenz M., Yamaguchi H., Wang Y., Singer R. H., Condeelis J., Imaging sites of N-WASP activity in lamellipodia and invadopodia of carcinoma cells. Current Biology 2004 14 8 697 703 2-s2.0-1942508987 10.1016/j.cub.2004.04.008 (Pubitemid 38503607)
41. Bourguignon L. Y. W., Zhu H., Shao L., Chen Y. W., CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. The Journal of Biological Chemistry 2001 276 10 7327 7336 2-s2.0-0035831463 10.1074/jbc.M006498200
42. Bourguignon L. Y. W., Singleton P. A., Diedrich F., Hyaluronan-CD44 interaction with Rac1-dependent protein kinase N- γ promotes phospholipase C γ 1 activation, Ca2+ signaling, and cortactin-cytoskeleton function leading to keratinocyte adhesion and differentiation. The Journal of Biological Chemistry 2004 279 28 29654 29669 2-s2.0-3142773619 10.1074/jbc.M403608200 (Pubitemid 38915849)
43. Wang Y., McNiven M. A., Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. The Journal of Cell Biology 2012 196 375 385
44. Gunthert U., Stauder R., Mayer B., Terpe H. J., Fink L., Friedrichs K., Are CD44 variant isoforms involved in human tumour progression? Cancer Surveys 1995 24 19 42 2-s2.0-0029004293
45. Stauder R., Eisterer W., Thaler J., Gunthert U., CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995 85 10 2885 2899 2-s2.0-0029054677
46. Seiter S., Schadendorf D., Herrmann K., Schneider M., Rösel M., Arch R., Tilgen W., Zöller M., Expression of CD44 variant isoforms in malignant melanoma. Clinical Cancer Research 1996 2 3 447 456 2-s2.0-0029944661 (Pubitemid 26100046)
47. Seiter S., Arch R., Reber S., Komitowski D., Hofmann M., Ponta H., Herrlich P., Matzku S., Zoller M., Prevention of tumor metastasis formation by anti-variant CD44. Journal of Experimental Medicine 1993 177 2 443 455 2-s2.0-0027408671 (Pubitemid 23117094)
48. Mulder J. W. R., Kruyt P. M., Sewnath M., Oosting J., Seldenrijk C. A., Weidema W. F., Offerhaus G. J. A., Pals S. T., Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. The Lancet 1994 344 8935 1470 1472 2-s2.0-0028131614 10.1016/S0140-6736(94)90290-9 (Pubitemid 24351702)
49. Wielenga V. J. M., van der Voort R., Mulder J. W. R., Kruyt P. M., Weidema W. F., Oosting J., Seldenrijk C. A., Van Krimpen C., Offerhaus G. J. A., Pals S. T., CD44 splice variants as prognostic markers in colorectal cancer. Scandinavian Journal of Gastroenterology 1998 33 1 82 87 2-s2.0-6844259864 10.1080/00365529850166257 (Pubitemid 28114074)
50. Fox S. B., Fawcett J., Jackson D. G., Collins I., Gatter K. C., Harris A. L., Gearing A., Simmons D. L., Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Research 1994 54 16 4539 4546 2-s2.0-0028133090 (Pubitemid 24273174)
51. Lesley J., Hyman R., Kincade P. W., CD44 and its interaction with extracellular matrix. Advances in Immunology 1993 54 271 335 2-s2.0-0027491845 (Pubitemid 23289255)
52. Naor D., Sionov R. V., Ish-Shalom D., CD44: structure, function, and association with the malignant process. Advances in Cancer Research 1997 71 241 319 2-s2.0-0030966842 (Pubitemid 27197761)
53. Friedrichs K., Franke F., Lisboa B. W., Kugler G., Gille I., Terpe H. J., Holzel F., Maass H., Gunthert U., CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Research 1995 55 22 5424 5433 2-s2.0-0028851930
54. Ekici S., Ayhan A., Kendi S., Özen H., Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score. Journal of Urology 2002 167 5 2037 2041 2-s2.0-0036226242 (Pubitemid 34309655)
55. Bennett K. L., Modrell B., Greenfield B., Bartolazzi A., Stamenkovic I., Peach R., Jackson D. G., Spring F., Aruffo A., Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. The Journal of Cell Biology 1995 131 6 1623 1633 2-s2.0-0029583425 10.1083/jcb.131.6.1623 (Pubitemid 26001764)
56. Jackson D. G., Bell J. I., Dickinson R., Timans J., Shields J., Whittle N., Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. The Journal of Cell Biology 1995 128 4 673 685 2-s2.0-0028809263 10.1083/jcb.128.4.673
57. Sleeman J. P., Kondo K., Moll J., Ponta H., Herrlich P., Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44. The Journal of Biological Chemistry 1997 272 50 31837 31844 2-s2.0-0031451346 10.1074/jbc.272.50.31837 (Pubitemid 28013335)
58. Orian-Rousseau V., Chen L., Sleeman J. P., Herrlich P., Ponta H., CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes and Development 2002 16 23 3074 3086 2-s2.0-0036896923 10.1101/gad.242602 (Pubitemid 35424194)
59. Orian-Rousseau V., Morrison H., Matzke A., Kastilan T., Pace G., Herrlich P., Ponta H., Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Molecular Biology of the Cell 2007 18 1 76 83 2-s2.0-33846077485 10.1091/mbc.E06-08-0674 (Pubitemid 46066712)